Key Highlights
- Net income was USD 458.6 million, or USD 17.02 per diluted share, against a net loss of USD 341.9 million, or USD 12.70, in the third quarter of 2025.
- A USD 588.2 million gain on Equity securities and a Loan receivable, including USD 583.2 million on the Sartorius stake, drove the swing.
- Net sales rose 0.5% to USD 656.4 million, and gross Margin narrowed to 50.1% from 52.6% on higher restructuring costs.
- Restructuring charges of USD 77.6 million were recorded in the quarter, plus a USD 49.8 million Impairment of acquired Celsee intangible assets.
A Paper Gain Swamps Operating Results
Bio-Rad Laboratories (NYSE:BIO) filed its Quarterly Report on November 4, 2026. Net Income attributable to the company was USD 458.6 million against a USD 341.9 million loss a year earlier, and Diluted Earnings per Share were USD 17.02 against a loss of USD 12.70. The swing came mainly from non-operating items: a USD 588.2 million gain from the change in fair Market Value of equity securities and a loan receivable, of which USD 583.2 million was a holding gain on its Investment in Sartorius. A year earlier, the same stake produced a holding loss of USD 505.1 million.
Flat Sales, Lower Margins and Restructuring
Net sales were USD 656.4 million, up 0.5% or about 0.7% on a currency-neutral basis. Clinical Diagnostics sales rose 2.7% to USD 401.8 million on quality systems and diabetes products, while Life Science sales fell 2.8% to USD 254.6 million on lower process chromatography sales and academic research weakness, partly offset by Droplet Digital PCR. Selling, general and administrative expense jumped to USD 257.1 million from USD 206.8 million on restructuring. Gross margin fell about 3.8 points in Life Science and 1.6 points in Clinical Diagnostics, which the filing ties to higher restructuring costs, while Research and Development expense held near USD 71.4 million. The effective tax rate was 14.9% against 20.7%.
Restructuring Plan, Cash and Middle East Risk
A restructuring plan launched July 31, 2026 is expected to cost about USD 80 million to USD 90 million before tax and to cut annual operating expenses by USD 30 million to USD 35 million by the end of 2027. Cash and equivalents were USD 465.3 million and short-term investments were USD 1.20 billion at September 30, 2026. Operating Cash Flow was USD 303.2 million for nine months against USD 367.3 million. The company has USD 1.2 billion of senior notes, and quarterly interest expense was USD 12.3 million. Management also said conflicts in the Middle East have hurt Demand and logistics in EMEA, especially Clinical Diagnostics, and it expects that to continue for the rest of 2026. China is a mid-single-digit share of year-to-date sales and remains uncertain, and about 61% of sales come from outside the United States.
Where Things Stand
Mostly through a mark-to-market gain, not through operations. Bio-Rad Laboratories (NYSE:BIO) reported earnings per share of USD 17.02, but sales grew only 0.5%, gross margin fell by 2.5 points (calculated) and restructuring costs weighed. Because the Sartorius stake is carried at fair value, results can swing sharply in either direction each quarter. The next markers are progress on the restructuring savings, stability in academic and China demand, and EMEA conditions.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...